Alex Philippidis Senior News Editor Genetic Engineering & Biotechnology News
Various cities are trying to attract more talent and incentives to meet demands of the life science industry.
The weak economy of the past four years combined with cutbacks due to mergers and acquisitions have helped consolidate U.S. biopharma activity further within the nation’s largest life sciences clusters. Yet that has not stopped several other U.S. regions from trying to carve out their own piece of the life science pie.
The real estate firm Jones Lang LaSalle (JLL) highlighted nine examples of what it called emerging bioclusters. The regions in descending order as ranked by JLL are Minneapolis, Raleigh-Durham, Seattle, Chicago, Denver, Houston, Florida, Atlanta, and Indianapolis.
Arguably, though, the first three clusters on their list are far past that status. Minneapolis’ cluster has long been focused on medical device manufacturers anchored by the Mayo Clinic. Research Triangle Park, which includes the cities of Raleigh and Durham, has attracted several biopharma giants including Biogen Idec and GlaxoSmithKline.
Seattle has a growing research base: Leroy Hood’s Institute for Systems Biology completed its move within the city to an expanded headquarters in May. Additionally, Fred Hutchinson Cancer Research Center expects to complete work on a new building this year. Seattle is also home to the Bill and Melinda Gates Foundation.
Erin Bovee, senior research analyst, life science with JLL, said the firm ranked 16 regions in which it does business on a scale of six equally weighted criteria: high-tech research and hospital/medical employment as a percentage of total employment; science and engineering graduate students (per 1,000 individuals aged 25–34); NIH funding; biotech and medical device venture capital funding in 2010 tracked by MoneyTree Report; R&D spending as a percentage of GDP; and size of academic and research institute facilities in square feet.
Chicago and Denver scored highest in percentage of science and engineering graduates (fifth and seventh best, respectively); Houston, in NIH funding (seventh); Florida and Atlanta, in research space (seventh and third, respectively); and Indianapolis, in biomedical employment (sixth).
Chicago hosted the 2010 BIO International Convention, while suburban Deerfield, IL, is home to the U.S. headquarters of Japanese pharma giants Takeda and Astellas. Lake Forest, IL, houses Hospira, which last month launched the first generic version of Merck & Co.’s Primaxin antibiotic in the U.S.
“You have the excellent academic institutions, and you have had a push from iBio (the Illinois Biotechnology Industry Organization), which has hundreds of companies here in Illinois trying to do something,” Bill Barrett, executive managing director, life sciences with Jones Lang LaSalle, pointed out to GEN. “And you’ve got great hospitals and research hospitals. It seems to just be lacking in the funding. I don’t think the funding from the state of Illinois is there either.”
Illinois has played catch-up in recent years to neighboring Wisconsin, which since 2003 has created and enhanced tax credit programs for angel and VC investors. Last year Gov. Pat Quinn (D) enacted a $10 million tax program to aid state-based angel investors in startups in Illinois. In October Quinn launched Advantage Illinois, a $78 million federally funded portfolio of programs to fund smaller businesses seeking capital.
Denver anchors a growing Colorado biopharma effort that will see the state divert part of the corporate sales taxes collected from biotech and cleantech companies between 2013 and 2023 to help fund startups in those industries under a law enacted in May by Gov. John Hickenlooper (D). Bio startups also saw welcome news earlier this month when the Fitzsimmons Redevelopment Authority announced plans for an $8 million, 37,000 sq. ft. “accelerator” space within its Bioscience Park for companies past the incubator stage.
Houston benefits from two research institutions that have proven as adept at winning NIH grant funding as in carrying out top-tier research. Baylor College of Medicine won $215.2 million in FY 2011, and University of Texas MD Anderson Cancer Center racked up $152.3 million in FY ’11. Additionally, the $3 billion Cancer Prevention and Research Institute of Texas, which since 2010 has awarded $570.75 million in awards, has recruited about 24 cancer scientists to Texas.
Florida has attracted more than a half-dozen research institutes by showering them with state tax incentives tied to promises of job creation. Policy initiatives were put in place a decade ago by then-governor Jeb Bush (R) and maintained by his successor Charlie Crist (R). But Crist’s successor, Gov. Rick Scott (R) sliced $4 billion from the state budget, including funds from an economic development program. The Jackson Laboratory was hoping to tap this money for a personalized medicine campus.
After the state told Jackson Lab to seek far less than the $100 million it wanted, the Bar Harbor, ME, institute withdrew its request in June. Four months later the laboratory agreed to build The Jackson Laboratory for Genomic Medicine in Farmington, CT; Connecticut’s legislature authorized $291 million in bond funding toward the project in October.
Florida is certainly not hurting for research institutes or academic space, though. The Sunshine State has 3.779 million square feet of it, according to JLL. Part of that space has been or is being built over the past decade for research institutions that include the Scripps Florida Research Institute, Max Planck Florida Institute, Sanford-Burnham Medical Research Institute, Torrey Pines Institute for Molecular Studies, The Vaccine and Gene Institute, and Mann Research Center.
Among JLL’s emerging bioclusters, only Atlanta has more research space than Florida at 4.474 million square feet. Atlanta has benefited from the presence of CDC and the American Cancer Society as well as its universities. Atlanta’s home state has seen its workforce rise 1.3%, or by 198 jobs, to 17,926 jobs in life science companies, according to Georgia Bio. That total is surpassed by the sum of life science research jobs at colleges and universities (16,393) and CDC (7,551).
Indianapolis has capitalized on the strengths of its workforce, according to JLL; Eli Lilly is headquartered in this region. Indianapolis has the largest concentration of Indiana’s life science workforce, according to Bio Crossroads. This includes 17,800 in drugs and pharmaceuticals, accounting for 35.5% of the total 50,000+ jobs . The figure has grown 21%, or by 8,800 jobs, since 2002.
As busy as emerging biopharma clusters have been in recent years, however, their activity has been overshadowed by the ongoing consolidation by big pharma and big biotech within the top two clusters. “There’s a fundamental recalibration of the pharmaceutical industry that is under way,” Dino Perazzo, an svp with real estate firm CB Richard Ellis (CBRE), told GEN.
“What that does more than anything is it brings attention to all of the pharmaceutical companies and all of the risk that they have to their revenues and their relatively weak pipelines to backfill them,” Perazzo noted. “You’ve got to go where the science is now. And that science is in Cambridge, Massachusetts, and the San Francisco Bay Area.”
As for emerging markets, “I don’t think they’re going away, but I don’t think 2012 or shortly thereafter is going to be the time at which those markets are going to grow,” added Perazzo, who is also a director on the advisory board of CBRE’s Global Life Science Group.
For example, Perazzo pointed out:
- Pfizer’s cardiovascular, metabolic, and endocrine diseases research unit moved this year to Cambridge, MA, from Groton, CT, while its neuroscience research unit plans a similar move next year. The units will eventually occupy a new building to be completed in the fourth quarter of 2013.
- Novartis plans to break ground in 2012 on a new 400,000 sq. ft. building for its Global Research Headquarters in Cambridge, MA.
- Sanofi has said that it is committed to expanding in Cambridge, MA, following its $20.1 billion acquisition of Genzyme earlier this year. The new Genzyme is now seeking between 50,000 and 100,000 square feet of space.
As long as big biotech and big pharma are scrambling to refill pipelines and slash costs, they will indeed steer significant activity to established clusters. Over time, though, that industry makeover is also supposed to involve outsourcing research and manufacturing operations as well as partnering with universities and smaller companies. At least some of that activity just might prompt companies to look beyond their home clusters and toward emerging areas. In the meantime, these new regions will have to prepare to address the challenges faced by the life science industry.
Alex Philippidis is senior news editor at Genetic Engineering & Biotechnology News.